Insulet Co. (NASDAQ:PODD) Shares Acquired by International Assets Investment Management LLC

International Assets Investment Management LLC grew its stake in Insulet Co. (NASDAQ:PODD) by 23,175.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 37,240 shares of the medical instruments supplier’s stock after buying an additional 37,080 shares during the period. International Assets Investment Management LLC owned 0.05% of Insulet worth $8,668,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Blue Trust Inc. increased its holdings in shares of Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 58 shares in the last quarter. UMB Bank n.a. raised its position in shares of Insulet by 81.0% in the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after buying an additional 81 shares during the last quarter. CVA Family Office LLC lifted its stake in shares of Insulet by 138.1% during the second quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after buying an additional 145 shares during the period. Massmutual Trust Co. FSB ADV raised its holdings in Insulet by 159.2% in the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 254 shares of the medical instruments supplier’s stock valued at $51,000 after acquiring an additional 156 shares during the last quarter. Finally, 1620 Investment Advisors Inc. acquired a new stake in shares of Insulet during the second quarter worth $52,000.

Insulet Trading Up 0.4 %

Shares of PODD stock opened at $231.53 on Friday. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.71 and a current ratio of 3.60. Insulet Co. has a 1 year low of $128.68 and a 1 year high of $243.98. The stock has a fifty day moving average of $226.09 and a two-hundred day moving average of $200.78. The firm has a market capitalization of $16.23 billion, a PE ratio of 42.10, a price-to-earnings-growth ratio of 4.36 and a beta of 1.21.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). Insulet had a return on equity of 30.73% and a net margin of 21.11%. The business had revenue of $488.50 million for the quarter, compared to analyst estimates of $488.00 million. During the same quarter last year, the firm posted $0.38 EPS. The company’s revenue was up 23.2% compared to the same quarter last year. As a group, research analysts expect that Insulet Co. will post 3.04 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on PODD. BTIG Research raised their price target on Insulet from $250.00 to $260.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Canaccord Genuity Group boosted their price target on Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Citigroup boosted their price target on Insulet from $250.00 to $275.00 and gave the stock a “buy” rating in a research report on Tuesday, October 1st. Barclays boosted their price target on Insulet from $200.00 to $220.00 and gave the stock an “equal weight” rating in a research report on Monday, August 12th. Finally, Piper Sandler boosted their price target on Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 17th. Three analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $242.29.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.